Literature DB >> 3856464

The adverse effect of prolonged prednisolone pretreatment in children with acute lymphoblastic leukemia.

T Révész, G Kardos, P Kajtár, D Schuler.   

Abstract

Between 1971 and 1981, 699 children were diagnosed to have acute lymphoblastic leukemia (ALL) in Hungary. 34 of these children had received prednisolone therapy prior to the establishment of the diagnosis. The most frequent presumptive diagnoses that prompted steroid treatment were aplastic conditions and arthritic disorders. Leukemia was diagnosed when the presenting symptoms reappeared usually several weeks after the initiation of steroid therapy and often following withdrawal of the drug. Initial leukemic burden, as judged by leukocyte count and hepatosplenomegaly, was smaller in these patients than in other children with leukemia at the time of diagnosis. Although they entered remission at the same rate as the other patients, the length of continuous complete remission was significantly shorter in the prednisolone pretreated group. It appears that prolonged prednisolone therapy given before remission induction imparts a distinct unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856464     DOI: 10.1002/1097-0142(19850415)55:8<1637::aid-cncr2820550804>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Childhood leukaemia masquerading as juvenile idiopathic arthritis.

Authors:  M J Murray; T Tang; C Ryder; D Mabin; J C Nicholson
Journal:  BMJ       Date:  2004-10-23

2.  Unresponsive asthma: Don't forget mediastinal masses.

Authors:  Matthew J Murray; James C Nicholson; Donna McShane
Journal:  BMJ       Date:  2008-03-08

3.  Characteristics of children with acute lymphoblastic leukemia presenting with arthropathy.

Authors:  Ninna Brix; Henrik Hasle; Steen Rosthøj; Troels Herlin
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

4.  Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Elizabeth A Raetz; Mignon L Loh; Meenakshi Devidas; Kelly Maloney; Leonard A Mattano; Eric Larsen; Andrew Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent Wood; Michael J Borowitz; Naomi Winick; Stephen P Hunger; William L Carroll
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

5.  Arthritic presentation of malignancies in children: a retrospective study from two centers in South India.

Authors:  Suma Balan; Mahesh Janarthanan
Journal:  Sudan J Paediatr       Date:  2022

6.  Predictive plain X-ray findings in distinguishing early stage acute lymphoblastic leukemia from juvenile idiopathic arthritis.

Authors:  Farhad Tafaghodi; Yahya Aghighi; Hadi Rokni Yazdi; Madjid Shakiba; Ali Adibi
Journal:  Clin Rheumatol       Date:  2009-07-21       Impact factor: 2.980

7.  Arthritic presentation of acute leukemia in children: experience from a tertiary care centre in North India.

Authors:  Deepali Gupta; Surjit Singh; Deepti Suri; Jasmina Ahluwalia; Reena Das; Neelam Varma
Journal:  Rheumatol Int       Date:  2009-07-25       Impact factor: 2.631

8.  Mediastinal masses masquerading as common respiratory conditions of childhood: a case series.

Authors:  A Saraswatula; D McShane; D Tideswell; G A A Burke; D M Williams; J C Nicholson; M J Murray
Journal:  Eur J Pediatr       Date:  2009-02-11       Impact factor: 3.183

9.  Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset.

Authors:  Mirian S Tamashiro; Nádia Emi Aikawa; Lucia Maria A Campos; Lílian Maria Cristofani; Vicente Odone-Filho; Clovis A Silva
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia.

Authors:  Sumit Gupta; Jason D Pole; Astrid Guttmann; Lillian Sung
Journal:  BMC Med Res Methodol       Date:  2013-05-30       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.